Your Article Summary
See Latest ArticlesSunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
British Journal of Cancer, 07/02/09
Thompson Coon JS et al. - In a study to explore the evidence from all available randomised clinical trials of sunitinib and bevacizumab, in combination with interferon-α (IFN-α), in treatment of advanced metastatic renal cell carcinoma (RCC), there is evidence to suggest that treatment with sunitinib and treatment with bevacizumab plus IFN has clinically relevant and statistically significant advantages over treatment with IFN alone in pts with metastatic RCC.
Methods- Systematic literature searches were performed in 6 electronic databases.
- Bibliographies of included studies were searched for further relevant studies.
- Individual conference proceedings were searched using their online interfaces.
- Studies were selected according to predefined criteria.
- All randomised clinical trials of sunitinib or bevacizumab in combination with IFN for treating advanced metastatic RCC, in accordance with the European licensed indication, were included.
- Study selection, data extraction, validation and quality assessment were performed by 2 reviewers with disagreements being settled by discussion.
- Effects of sunitinib and bevacizumab (in combination with IFN-α) on progression-free survival (PFS) were compared indirectly using Bayesian Markov Chain Monte-Carlo (MCMC) sampling in Win BUGS, with IFN as a common comparator.
- 3 studies were included.
- Median PFS was significantly prolonged with both interventions (from 5 mos to between 8 and 11 mos) compared with IFN.
- Overall survival was also prolonged, compared with IFN, although published data are not fully mature.
- Indirect comparison suggests that sunitinib is superior to bevacizumab plus IFN in terms of PFS.
Related Articles
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
British Journal of Cancer, 10/19/09
Relevance Score: 89%
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
Investigational New Drugs, 10/08/09
Relevance Score: 88%
Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib
Clinical Cancer Research, 11/16/09
Relevance Score: 87%
Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature
Medical Oncology, 10/23/09
Relevance Score: 87%
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-2a compared with sunitinib
British Journal of Cancer, 11/20/09
Relevance Score: 84%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical Benefit of Allogeneic Melanoma Cell Lysate–Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients
Clinical Cancer Research, 12/11/09
Radiation Therapy for Rectal Cancer: Current Status and Future Directions
Cancer Control, 12/11/09
Current Progress in Targeted Therapy for Colorectal Cancer
Cancer Control, 12/11/09
Today in Renal/Urologic...keeping you current
Receive free subspecialty "5-minute updates" via email
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma
Clinical Cancer Research, 12/11/09
Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype
The Journal of Pathology, 12/11/09
Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence
Cancer, 12/11/09